ReAlta Life Sciences
Business Services · Virginia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5665 Lowery Rd Ste 100, Norfolk, Virgini...Phone Number
(757) 901-0460Website
www.realtalifesciences.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About ReAlta Life Sciences
ReAlta Life Sciences is viewed by third parties as a clinical-stage biotechnology company focused on developing innovative therapies that target inflammation and rare diseases. It leverages a proprietary platform to create dual-acting peptide treatments designed to regulate immune system responses and improve outcomes in conditions with limited treatment options.External sources describe the company as operating within the biopharmaceutical research and development space, advancing therapies across areas such as neurology, pulmonary disease, and hematology. Its approach emphasizes translating scientific discoveries into clinically viable treatments aimed at addressing serious and life-threatening inflammatory conditionsExplore more
ReAlta Life Sciences Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ReAlta Life Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if ReAlta Life Sciences had a recent Job posting/layoffs
Check out if ReAlta Life Sciences is spiking on competitors!
Check if ReAlta Life Sciences has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once ReAlta Life Sciences has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on ReAlta Life Sciences recently announced quarterly report
ReAlta Life Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at ReAlta Life Sciences
Product Launch: Get notified when ReAlta Life Sciences launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to ReAlta Life Sciences
Compare insights from companies similar to ReAlta Life Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
ReAlta Life Sciences
$6.3M
11-50
Private
$86M
2018
Kenji CunnionCo-Inventor, Chief Medical Officer & Director
Company Profile Activity
Activity Insights
ReAlta Life Sciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ReAlta Life Sciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ReAlta Life Sciences.
ReAlta Life Sciences financials insights
Gather financial insights about ReAlta Life Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$26M
2021
Other Financing Round
$20M
2026
Unspecified
$40M
ReAlta Life Sciences Tech Stack
A closer look at the technologies used by ReAlta Life Sciences
See more technologies
Most Recent Scoops
Funding
Funding
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Promotion
Executive Move
John Rickman has recently been promoted from Chief Financial Officer to the role of Interim Chief Executive Officer.
Executive Moves, Promotion
New Hire
Executive Move
Executive Moves, New Hire
ReAlta Life Sciences News & Media
ReAlta Life Sciences Secures European Orphan Drug Status for Graft-vs-Host Disease Treatment
By Karen Roman ReAlta Life Sciences, Inc. said it was granted Orphan Drug Designation by the European Medicines Agency (EMA) for RLS-0071 (pegtarazimod), to treat Graft-versus-Host Disease (GvHD). The designation was supported by preliminary data from the company’s Phase 2 trial and follows FDA Orphan Drug and Fast Track designations received in 2024, it stated. “Receiving […]ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer
By Karen Roman ReAlta Life Sciences, Inc. said it designated Ellen Lubman as Chief Business Officer to supervise business development, capital formation and corporate strategy. Ms. Lubman has nearly 25 years of experience across small to large-cap private and public biopharmaceutical companies with a track record in strategic, transactional, and operational roles, the company stated. […]ReAlta Life Sciences Announces New Inflammatory Biomarker Data from Acute Exacerbations of Chronic Obstructive Pulmonary Disease Program at American Thoracic Society 2025 International Conference
NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced a poster presentation featuring new analysis of clinical data from its acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) program at the American Thoracic Society (ATS) 2025 International Conference, taking place MayReAlta Life Sciences Announces New Clinical Data for RLS-0071 (pegtarazimod) from Hypoxic Ischemic Encephalopathy Program at Pediatric Academic Societies 2025 Meeting
NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced new clinical data from its hypoxic ischemic encephalopathy (HIE) program, to be presented at the Pediatric Academic Societies (PAS) Annual Meeting, taking place April 24-28, 2025 in Honolulu, Hawaii. First Human Evidence of Predicted Inf
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding ReAlta Life Sciences
Sign Up For FreeTo access detailed company insights
ReAlta Life Sciences is viewed by third parties as a clinical-stage biotechnology company focused on developing innovative therapies that target inflammation and rare diseases. It leverages a proprietary platform to create dual-acting peptide treatments designed to regulate immune system responses and improve outcomes in conditions with limited tre... Read More
